Recursion Pharmaceuticals' AI-based approach has the potential to transform the pharmaceutical industry. However, it is still chasing clinical wins that would demonstrate the power of its strategy.

We independently review everything we recommend. When you buy through our links, we may earn a commission. Learn more› By Rory Evans Rory Evans is a writer focused on skin-care and beauty products.

In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...

Hepatitis C is liver inflammation and damage caused by infection with the hepatitis C virus. Hep C can cause a mild illness that lasts a short time (acute) or a serious illness that can last the rest ...

When you feel a cold coming on, you might reach for a vitamin C supplement for its health-strengthening properties. “Vitamin C is an essential nutrient, which means that we need to get it from food or ...

Katelyn Peters has a writer and editor for more than five years who focuses on both investing and personal finance content. In addition to her experience in finance, she is also a volunteer editorial ...

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the Best High Volume Penny Stocks to Buy. On December 17, Priyanka Grover from J.P. Morgan upgraded Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX ...

Recursion Pharmaceuticals' (NASDAQ: RXRX) stock price has seen a dramatic increase, not due to company-specific news or drug announcements, but rather due to actions taken by artificial intelligence ...